Antipsychotic drugs in dementia: A necessary evil?

Maturitas

Volumn 68, Issue 2, 2011, Pages 109-110

  Thomas, Alan J ^a  

^a NEWCASTLE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ARIPIPRAZOLE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE;

BEHAVIOR DISORDER; CLINICAL PRACTICE; DEMENTIA; DRUG EFFICACY; EDITORIAL; HUMAN; PRESCRIPTION; PSYCHOSIS; UNITED KINGDOM;

AGGRESSION; ANTIPSYCHOTIC AGENTS; DEMENTIA; HUMANS; PSYCHOTIC DISORDERS;

EID: 78651408040     PISSN: 03785122     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.maturitas.2010.11.015     Document Type: Editorial

References (7)

1. Banerjee S. The use of antipsychotic medication for people with dementia: time for action. 2009.
2. C. Ballard The dementia antipsychotic withdrawal trial (DART-AD): long-term follow-up of a randomised placebo-controlled trial Lancet Neurology 8 2 2009 151 157
3. H.C. Kales Mortality risk in patients with dementia treated with antipsychotics versus other psychiatric medications American Journal of Psychiatry 164 10 2007 1568 1576 quiz 1623
4. L.S. Schneider, K.S. Dagerman, and P. Insel Risk of death with atypical antipsychotic drug treatment for dementia: meta-analysis of randomized placebo-controlled trials [see comment] JAMA 294 15 2005 1934 1943
5. C. Ballard Quetiapine and rivastigmine and cognitive decline in Alzheimer's disease: randomised double blind placebo controlled trial BMJ 330 7496 2005 p874
6. L.S. Schneider, K. Dagerman, and P.S. Insel Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials American Journal of Geriatric Psychiatry 14 3 2006 191 210
7. C.G. Ballard A 3 month, randomised, placebo-controlled, neuroleptic discontinuation study in 100 people with dementia: the neuropsychiatric inventory median cut-off is a predictor of clinical outcome Journal of Clinical Psychiatry 65 1 2004 114 119